Blog

Kite Pharma Asks FDA to Pave Way Toward It Holding Clinical Trials of Its Myeloma Therapy KITE-585 – Myeloma Research News


Myeloma Research News

Kite Pharma Asks FDA to Pave Way Toward It Holding Clinical Trials of Its Myeloma Therapy KITE-585
Myeloma Research News
Because the protein is crucial to myeloma cells' survival and growth, it is a good target for chimeric antigen receptor T-cell treatments, also known as CAR T-cell therapies. Those therapies use a patient's own immune cells to combat their disease. The
Kite Pharma, Inc. (NASDAQ:KITE) Traded 21.0% Above Its 50 Day AverageModern Readers


Kite Pharma, Inc. (NASDAQ:KITE) Stock Closed Much Higher Than …HugoPress
Kite Pharma, Inc. (NASDAQ:KITE) Traded Significantly Above Its 50 …Highlight Press
Finance Daily
all 21 news articles »

2017-08-23 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.